PLOD3

Across TCGA pan-cancer cohorts, PLOD3 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated PLOD3 data layer compared with 6 for mutation status and 7 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher PLOD3 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PLOD3 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

MESO, KICH, and UVM are the cancer types where PLOD3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.254	0.501	<.001	130	view →
KICH	OS	Tertile	II,III,IV	0.512	1.000	<.001	106	view →
UVM	OS	Median	II,III,IV	0.439	0.827	<.001	98	view →
LUSC	DFS	Quartile	II,III,IV	0.496	0.751	.002	74	view →
ACC	DFS	Median	All	0.412	0.756	<.001	71	view →
LIHC	DFS	Median	All	0.466	0.615	<.001	64	view →
LGG	OS	Median	All	0.332	0.553	<.001	54	view →
CESC	DFS	Median	All	0.416	0.643	<.001	50	view →
STAD	DFS	Quartile	All	0.188	0.689	.007	49	view →
BRCA	DFS	Median	All	0.878	0.923	.008	49	view →
COAD	DFS	Quartile	All	0.586	0.771	.002	40	view →
BLCA	DFS	Median	All	0.156	0.548	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

PLOD3–MESO (OS)

Open the MESO breakdown →